Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)

The National Institutes of Health (NIH), operating under the U.S. Department of Health and Human Services, has issued a Notice of Funding Opportunity (NOFO) under the Funding Opportunity Number RFA-CA-25-007. This opportunity supports revision applications specifically targeting currently funded NCI P50 specialized centers. These centers are encouraged to incorporate novel technologies, particularly those developed through the NCI's Innovative Molecular Analysis Technologies (IMAT) program, with the objective of accelerating cancer research through the integration of innovative and independently validated technical approaches or devices. As part of the IMAT program's broader mission, this grant supports interdisciplinary collaboration and innovation in the field of cancer research. The grant's primary objective is to enhance or expand the scope of the parent study already underway at NCI P50 centers. Applicants must focus on applying new technologies supported by the IMAT initiative to existing research questions or projects, with the goal of expediting discovery and applicability in cancer-related domains. These revisions should serve to independently validate the emerging technologies while fostering broader usability across the cancer research community. Eligible applicants include a broad range of organizations: public and state-controlled institutions of higher education, private higher education institutions, nonprofits (both with and without 501(c)(3) status), small businesses, for-profit organizations, city and county governments, special district governments, state and tribal governments (both Federally recognized and not), school districts, and other eligible entities such as Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), and foreign organizations. This inclusive eligibility encourages diverse participation, fostering a more expansive innovation environment. There is no cost-sharing or matching requirement associated with this grant opportunity. The NIH anticipates awarding approximately three grants, each with a maximum funding ceiling of $150,000. The estimated total funding allocated for this NOFO is also $150,000, indicating that each award may receive a similar amount. The grant allows flexibility in the integration of new tools and methods, so long as they directly enhance the original P50 project. The application period opened on December 9, 2025, and will remain open through the same date. There are no pre-application requirements such as Letters of Intent or Concept Papers explicitly required. Applications are submitted through Grants.gov, and all applicants must adhere to NIH submission protocols. Evaluation criteria focus on the scientific merit of the proposed revision, the relevance and readiness of the new technology, and its potential to accelerate discovery within cancer research frameworks. Contact for this opportunity is NIH Grants Information, available via email at [email protected]. The official closing date for submissions is December 9, 2025. No recurrence pattern is stated for this NOFO, and it appears to be a one-time opportunity. Additional information can be accessed through the official NIH grants page linked in the opportunity description.